Copyright Reports & Markets. All rights reserved.

Global Primary Biliary Cholangitis Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Ursodeoxycholic Acid (UDCA)
      • 1.4.3 Obeticholic Acid (Ocaliva)
    • 1.5 Market by Application
      • 1.5.1 Global Primary Biliary Cholangitis Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Primary Biliary Cholangitis Treatment Market Size
    • 2.2 Primary Biliary Cholangitis Treatment Growth Trends by Regions
      • 2.2.1 Primary Biliary Cholangitis Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Primary Biliary Cholangitis Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Primary Biliary Cholangitis Treatment Market Size by Manufacturers
      • 3.1.1 Global Primary Biliary Cholangitis Treatment Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Primary Biliary Cholangitis Treatment Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Primary Biliary Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Primary Biliary Cholangitis Treatment Key Players Head office and Area Served
    • 3.3 Key Players Primary Biliary Cholangitis Treatment Product/Solution/Service
    • 3.4 Date of Enter into Primary Biliary Cholangitis Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Primary Biliary Cholangitis Treatment Market Size by Type (2014-2019)
    • 4.2 Global Primary Biliary Cholangitis Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Primary Biliary Cholangitis Treatment Market Size (2014-2019)
    • 5.2 Primary Biliary Cholangitis Treatment Key Players in United States
    • 5.3 United States Primary Biliary Cholangitis Treatment Market Size by Type
    • 5.4 United States Primary Biliary Cholangitis Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Primary Biliary Cholangitis Treatment Market Size (2014-2019)
    • 6.2 Primary Biliary Cholangitis Treatment Key Players in Europe
    • 6.3 Europe Primary Biliary Cholangitis Treatment Market Size by Type
    • 6.4 Europe Primary Biliary Cholangitis Treatment Market Size by Application

    7 China

    • 7.1 China Primary Biliary Cholangitis Treatment Market Size (2014-2019)
    • 7.2 Primary Biliary Cholangitis Treatment Key Players in China
    • 7.3 China Primary Biliary Cholangitis Treatment Market Size by Type
    • 7.4 China Primary Biliary Cholangitis Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Primary Biliary Cholangitis Treatment Market Size (2014-2019)
    • 8.2 Primary Biliary Cholangitis Treatment Key Players in Japan
    • 8.3 Japan Primary Biliary Cholangitis Treatment Market Size by Type
    • 8.4 Japan Primary Biliary Cholangitis Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Primary Biliary Cholangitis Treatment Market Size (2014-2019)
    • 9.2 Primary Biliary Cholangitis Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Primary Biliary Cholangitis Treatment Market Size by Type
    • 9.4 Southeast Asia Primary Biliary Cholangitis Treatment Market Size by Application

    10 India

    • 10.1 India Primary Biliary Cholangitis Treatment Market Size (2014-2019)
    • 10.2 Primary Biliary Cholangitis Treatment Key Players in India
    • 10.3 India Primary Biliary Cholangitis Treatment Market Size by Type
    • 10.4 India Primary Biliary Cholangitis Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Primary Biliary Cholangitis Treatment Market Size (2014-2019)
    • 11.2 Primary Biliary Cholangitis Treatment Key Players in Central & South America
    • 11.3 Central & South America Primary Biliary Cholangitis Treatment Market Size by Type
    • 11.4 Central & South America Primary Biliary Cholangitis Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Novartis
      • 12.1.1 Novartis Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.1.4 Novartis Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.1.5 Novartis Recent Development
    • 12.2 Bristol-Myers Squibb
      • 12.2.1 Bristol-Myers Squibb Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.2.4 Bristol-Myers Squibb Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.2.5 Bristol-Myers Squibb Recent Development
    • 12.3 Pfizer
      • 12.3.1 Pfizer Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.3.4 Pfizer Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.3.5 Pfizer Recent Development
    • 12.4 GlaxoSmithKline
      • 12.4.1 GlaxoSmithKline Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.4.4 GlaxoSmithKline Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.4.5 GlaxoSmithKline Recent Development
    • 12.5 Teva Pharmaceutical
      • 12.5.1 Teva Pharmaceutical Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.5.4 Teva Pharmaceutical Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.5.5 Teva Pharmaceutical Recent Development
    • 12.6 Retrophin
      • 12.6.1 Retrophin Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.6.4 Retrophin Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.6.5 Retrophin Recent Development
    • 12.7 Lumena Pharmaceuticals
      • 12.7.1 Lumena Pharmaceuticals Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.7.4 Lumena Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.7.5 Lumena Pharmaceuticals Recent Development
    • 12.8 Intercept Pharmaceuticals
      • 12.8.1 Intercept Pharmaceuticals Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Primary Biliary Cholangitis Treatment Introduction
      • 12.8.4 Intercept Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2014-2019)
      • 12.8.5 Intercept Pharmaceuticals Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There's no cure for primary biliary cholangitis, but medications are available to help slow the progression of the disease and prevent complications. Options include: Ursodeoxycholic acid (UDCA) and Obeticholic acid (Ocaliva).
      In 2018, the global Primary Biliary Cholangitis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Primary Biliary Cholangitis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Biliary Cholangitis Treatment development in United States, Europe and China.

      The key players covered in this study
      Novartis
      Bristol-Myers Squibb
      Pfizer
      GlaxoSmithKline
      Teva Pharmaceutical
      Retrophin
      Lumena Pharmaceuticals
      Intercept Pharmaceuticals

      Market segment by Type, the product can be split into
      Ursodeoxycholic Acid (UDCA)
      Obeticholic Acid (Ocaliva)

      Market segment by Application, split into
      Hospitals
      Clinics
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Primary Biliary Cholangitis Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Primary Biliary Cholangitis Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Primary Biliary Cholangitis Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now